BRTX
Price
$0.22
Change
-$0.00 (-0.00%)
Updated
Aug 21 closing price
Capitalization
5.49M
One day until earnings call
Intraday BUY SELL Signals
GRCE
Price
$2.20
Change
+$0.06 (+2.80%)
Updated
Aug 21 closing price
Capitalization
46.28M
Intraday BUY SELL Signals
Interact to see
Advertisement

BRTX vs GRCE

BRTX vs GRCE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BRTX vs. GRCE commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRTX is a Hold and GRCE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (BRTX: $0.22 vs. GRCE: $2.20)
Brand notoriety: BRTX and GRCE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BRTX: 21% vs. GRCE: 29%
Market capitalization -- BRTX: $5.49M vs. GRCE: $46.28M
BRTX [@Biotechnology] is valued at $5.49M. GRCE’s [@Biotechnology] market capitalization is $46.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BRTX’s FA Score shows that 1 FA rating(s) are green whileGRCE’s FA Score has 0 green FA rating(s).

  • BRTX’s FA Score: 1 green, 4 red.
  • GRCE’s FA Score: 0 green, 5 red.
According to our system of comparison, BRTX is a better buy in the long-term than GRCE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BRTX’s TA Score shows that 6 TA indicator(s) are bullish while GRCE’s TA Score has 5 bullish TA indicator(s).

  • BRTX’s TA Score: 6 bullish, 4 bearish.
  • GRCE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BRTX is a better buy in the short-term than GRCE.

Price Growth

BRTX (@Biotechnology) experienced а -4.69% price change this week, while GRCE (@Biotechnology) price change was +1.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

BRTX is expected to report earnings on Aug 24, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GRCE($46.3M) has a higher market cap than BRTX($5.49M). GRCE YTD gains are higher at: -36.416 vs. BRTX (-81.677). GRCE has higher annual earnings (EBITDA): -11.24M vs. BRTX (-14.01M). GRCE has more cash in the bank: 18.7M vs. BRTX (3.59M). BRTX has higher revenues than GRCE: BRTX (358K) vs GRCE (0).
BRTXGRCEBRTX / GRCE
Capitalization5.49M46.3M12%
EBITDA-14.01M-11.24M125%
Gain YTD-81.677-36.416224%
P/E RatioN/AN/A-
Revenue358K0-
Total Cash3.59M18.7M19%
Total Debt42.4KN/A-
FUNDAMENTALS RATINGS
BRTX vs GRCE: Fundamental Ratings
BRTX
GRCE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
39
Fair valued
PROFIT vs RISK RATING
1..100
10067
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
6576
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BRTX's Valuation (18) in the null industry is in the same range as GRCE (39) in the Pharmaceuticals Other industry. This means that BRTX’s stock grew similarly to GRCE’s over the last 12 months.

GRCE's Profit vs Risk Rating (67) in the Pharmaceuticals Other industry is somewhat better than the same rating for BRTX (100) in the null industry. This means that GRCE’s stock grew somewhat faster than BRTX’s over the last 12 months.

GRCE's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as BRTX (100) in the null industry. This means that GRCE’s stock grew similarly to BRTX’s over the last 12 months.

BRTX's Price Growth Rating (65) in the null industry is in the same range as GRCE (76) in the Pharmaceuticals Other industry. This means that BRTX’s stock grew similarly to GRCE’s over the last 12 months.

BRTX's P/E Growth Rating (100) in the null industry is in the same range as GRCE (100) in the Pharmaceuticals Other industry. This means that BRTX’s stock grew similarly to GRCE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BRTXGRCE
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
BRTX
Daily Signal:
Gain/Loss:
GRCE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VTCAX94.730.70
+0.74%
Vanguard Communication Svcs Idx Admiral
ELDFX23.820.08
+0.34%
Elfun Diversified
CCALX69.960.16
+0.23%
Conestoga Small Cap Institutional
APHWX12.130.01
+0.08%
Artisan Value Income Institutional
JRSTX12.73N/A
N/A
JH Adaptive Risk Mgd U.S. Eq T

BRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BRTX has been loosely correlated with TCRT. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if BRTX jumps, then TCRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BRTX
1D Price
Change %
BRTX100%
-2.40%
TCRT - BRTX
33%
Loosely correlated
-2.49%
EDIT - BRTX
31%
Poorly correlated
+5.78%
MCRB - BRTX
31%
Poorly correlated
-0.22%
GRCE - BRTX
28%
Poorly correlated
+2.80%
AIM - BRTX
27%
Poorly correlated
+2.09%
More